- JP-listed companies
- Nano Holdings, Inc.
- Balance sheet
Nano Holdings, Inc. (4571) Balance sheet
Market cap
¥8.5B
P/E ratio
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Cash and cash equivalents | - | 13,666 | 12,081 | 9,395 | 3,689 | 4,567 | 4,471 | 3,892 | 3,545 | 2,812 | 2,078 | 1,707 | 4,910 |
| Marketable securities, current | - | 105 | 1,679 | 2,374 | 2,719 | 2,000 | 3,000 | 2,511 | 2,400 | 1,632 | 2,200 | 1,798 | - |
| Inventories | - | - | 17 | 17 | 26 | 27 | - | - | - | - | - | - | - |
| Total current assets | - | 14,209 | 14,317 | 12,442 | 6,841 | 6,986 | 7,920 | 6,902 | 6,304 | 4,669 | 4,462 | 3,622 | 5,199 |
| Property, plant and equipment, net | - | 169 | 62 | 162 | 58 | 3 | 0 | 4 | 7 | - | - | - | - |
| Marketable securities, non-current | - | 113 | 788 | 128 | 518 | 1,371 | 817 | 687 | 597 | 886 | 358 | 222 | 336 |
| Total non-current assets | - | 495 | 1,070 | 497 | 786 | 1,582 | 1,025 | 919 | 832 | 1,116 | 609 | 375 | 707 |
| Total assets | - | 14,704 | 15,386 | 12,939 | 7,627 | 8,568 | 8,945 | 7,821 | 7,136 | 5,784 | 5,071 | 3,997 | 5,906 |
| Total current liabilities | - | 173 | 232 | 370 | 451 | 178 | 148 | 265 | 361 | 364 | 487 | 1,203 | 984 |
| Total non-current liabilities | - | 29 | 3,026 | 2,502 | 2,515 | 2,510 | 27 | 56 | 1,208 | 1,167 | 1,163 | 54 | 1,357 |
| Total liabilities | - | 202 | 3,258 | 2,872 | 2,965 | 2,689 | 176 | 321 | 1,569 | 1,531 | 1,650 | 1,257 | 2,341 |
| Retained earnings | - | -7,111 | -9,649 | -12,325 | -17,741 | -1,809 | -3,818 | -2,836 | -4,717 | -1,372 | -2,152 | -2,987 | -3,931 |
| Stockholders' equity | 13,597 | 14,502 | 12,129 | 10,067 | 4,662 | 5,880 | 8,769 | 7,500 | 5,567 | 4,253 | 3,421 | 2,740 | 3,566 |